JP2024511353A - リスペリドン及び生分解性ポリマーを含む長時間作用型注射用製剤 - Google Patents

リスペリドン及び生分解性ポリマーを含む長時間作用型注射用製剤 Download PDF

Info

Publication number
JP2024511353A
JP2024511353A JP2023556936A JP2023556936A JP2024511353A JP 2024511353 A JP2024511353 A JP 2024511353A JP 2023556936 A JP2023556936 A JP 2023556936A JP 2023556936 A JP2023556936 A JP 2023556936A JP 2024511353 A JP2024511353 A JP 2024511353A
Authority
JP
Japan
Prior art keywords
risperidone
formulation
long
acting injectable
poly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023556936A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024511353A5 (enExample
Inventor
メレンレンダー ワグナー アヴィア
エルガート ヴァリスキー アンナ
ハラリー エラン
Original Assignee
メドインセルル エス．エー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メドインセルル エス．エー． filed Critical メドインセルル エス．エー．
Publication of JP2024511353A publication Critical patent/JP2024511353A/ja
Publication of JP2024511353A5 publication Critical patent/JP2024511353A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2023556936A 2021-03-17 2022-03-17 リスペリドン及び生分解性ポリマーを含む長時間作用型注射用製剤 Pending JP2024511353A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163162272P 2021-03-17 2021-03-17
US63/162,272 2021-03-17
IB2021052248 2021-03-17
IBPCT/IB2021/052248 2021-03-17
US202163208860P 2021-06-09 2021-06-09
US63/208,860 2021-06-09
US202163270174P 2021-10-21 2021-10-21
US63/270,174 2021-10-21
PCT/EP2022/057009 WO2022195018A1 (en) 2021-03-17 2022-03-17 Long acting injectable formulation comprising risperidone and biodegradable polymers

Publications (2)

Publication Number Publication Date
JP2024511353A true JP2024511353A (ja) 2024-03-13
JP2024511353A5 JP2024511353A5 (enExample) 2025-04-02

Family

ID=81307068

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023556936A Pending JP2024511353A (ja) 2021-03-17 2022-03-17 リスペリドン及び生分解性ポリマーを含む長時間作用型注射用製剤

Country Status (10)

Country Link
US (2) US20240148641A1 (enExample)
EP (1) EP4308077A1 (enExample)
JP (1) JP2024511353A (enExample)
KR (1) KR20230158088A (enExample)
AU (1) AU2022236485A1 (enExample)
BR (1) BR112023018652A2 (enExample)
CA (1) CA3208006A1 (enExample)
IL (1) IL304980A (enExample)
MX (1) MX2023010925A (enExample)
WO (1) WO2022195018A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026501805A (ja) * 2023-01-10 2026-01-16 メドインセルル エス．エー． オランザピン組成物及び使用の方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014501253A (ja) * 2010-12-24 2014-01-20 サムヤン バイオファーマシューティカルズ コーポレイション 水難溶性薬物含有徐放性微小粒子及びその製造方法
JP2014502613A (ja) * 2010-12-29 2014-02-03 メドインセルル 生分解性薬物送達組成物
CN107213136A (zh) * 2017-06-07 2017-09-29 广州帝奇医药技术有限公司 一种长效缓释药物制剂及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012010195A2 (pt) * 2009-10-30 2016-04-26 Janssen Pharmaceutica Nv regime de dosagem associado a ésteres de paliperidona injetável de longa ação
US10463607B2 (en) * 2010-05-31 2019-11-05 Laboratorios Farmaceutics Rofi S.A. Antipsychotic Injectable Depot Composition
EP2866837B1 (en) 2012-06-27 2022-12-14 Medincell S.A. Biodegradable drug delivery for hydrophobic compositions
US20190015415A1 (en) * 2015-09-30 2019-01-17 Indivior Uk Limited Methods for treating schizophrenia
WO2020154315A1 (en) * 2019-01-22 2020-07-30 Indivior Uk Limited Methods for treating schizophrenia
MX2022003051A (es) * 2019-09-13 2022-06-14 Medincell S A Formulaciones para la administracion de farmacos.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014501253A (ja) * 2010-12-24 2014-01-20 サムヤン バイオファーマシューティカルズ コーポレイション 水難溶性薬物含有徐放性微小粒子及びその製造方法
JP2014502613A (ja) * 2010-12-29 2014-02-03 メドインセルル 生分解性薬物送達組成物
CN107213136A (zh) * 2017-06-07 2017-09-29 广州帝奇医药技术有限公司 一种长效缓释药物制剂及其制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KYOKO HIGASHI ET AL., THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, vol. 3, no. 4, JPN7026001384, 4 February 2013 (2013-02-04), pages 200 - 218, ISSN: 0005828984 *
TAISHIRO KISHIMOTO ET AL., LANCET PSYCHIATRY, vol. 8, no. 5, JPN6026012715, May 2021 (2021-05-01), pages 387 - 404, ISSN: 0005828983 *

Also Published As

Publication number Publication date
BR112023018652A2 (pt) 2023-10-03
MX2023010925A (es) 2023-09-27
AU2022236485A1 (en) 2023-08-24
US12329851B2 (en) 2025-06-17
EP4308077A1 (en) 2024-01-24
WO2022195018A1 (en) 2022-09-22
US20240148641A1 (en) 2024-05-09
KR20230158088A (ko) 2023-11-17
US20240325293A1 (en) 2024-10-03
CA3208006A1 (en) 2022-09-22
IL304980A (en) 2023-10-01

Similar Documents

Publication Publication Date Title
TW202523284A (zh) 用於治療子宮內膜癌的方法、組成物和組合
US20250268817A1 (en) Drug delivery formulations
US11324751B1 (en) Dosing regimens associated with extended release paliperidone injectable formulations
US11439647B2 (en) Dosing regimens associated with extended release paliperidone injectable formulations
JP2023552329A (ja) 持続放出パリペリドン注射可能製剤に関連する投与レジメン
CN116348095A (zh) 含有神经活性类固醇的药物组合物及其用途
US12329851B2 (en) Long acting injectable formulation comprising risperidone and biodegradable polymers
ES3055278T3 (en) Olanzapine compositions and methods of use
CN116997323A (zh) 包含利培酮和可生物降解的聚合物的长效可注射制剂
BR122025009310A2 (pt) Formulações de entrega de fármaco
HK40120254B (en) Olanzapine compositions and methods of use
HK40120254A (en) Olanzapine compositions and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250314

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250324

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20250825

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260331